Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Temodar Confirmatory Trial To Test Combination Use With BCNU

Executive Summary

A Phase IV confirmatory trial will explore the combination of Schering's Temodar (temozolomide) with BCNU in addition to comparing the oncologic agent to BCNU head to head in anaplastic astrocytoma. The trial is required following the accelerated approval of temozolomide Aug. 11.

You may also be interested in...



Temodal Melanoma Symptom Correlation Analysis Suggested By Cmte.

Correlation of symptom improvements to tumor response rate would be one way to demonstrate efficacy of Schering-Plough's Temodal in patients with malignant melanoma, members of FDA's Oncologic Drugs Advisory Committee suggested March 23.

Schering Temodal Tumor Response Supports Astrocytoma, Not Glioblastoma

Schering-Plough's Temodal (temozolomide) should be granted accelerated approval based on tumor response rates for treatment of anaplastic astrocytoma in patients who relapse following treatment with a nitrosourea (BCNU or CCNU) and procarbazine, the Oncologic Drugs Advisory Committee recommended Jan. 12.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS034692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel